Table 3. Open in new tab Characteristics...

Patient No.	Age, y	Follow-up Duration, y	BMI, SDS	Anterior Pituitary Dysfunction^a	Neuro- Developmental Delay	Seizures	Visual Impairment	Use of Sleep Medication	Duration of Enteral Nutritional and Fluid Support, y	DDAVP Treatment at the Last Evaluation	DDAVP Oral Melt/Tablets
1	5.0	4.9	0.5	GH, TSH, ACTH	Severe	Yes	Yes	Yes	—	Yes	105	6.8
2	8.1	7.8	−1.7	GH, TSH, ACTH	Moderate	No	Yes	No	—	Yes	30	1.6
3	1.5	1.3	2.5	GH, TSH, ACTH	Severe	Yes	Yes	Yes	0.3	Yes	15	1.2
4	16.4	16.0	−0.2	GH, TSH	Severe	Yes	Yes	No	—	Yes	85	2.1^b
5	3.1	2.5	0.2	GH	Moderate	No	Yes	No	—	Yes	150	10.3
6	20.0	19.8	2.3	No	Moderate	No	No	No	—	Yes	700	12.7^b
7	18.4	18.3	0.6	GH, TSH, ACTH, FSH-LH	Absent	No	No	No	—	Yes	180	3.1
8	16.8	16.8	1.8	GH, TSH, ACTH, FSH-LH	Absent	No	No	No	—	Stopped at the age 2.5 y	—	—
9	6.2	6.0	2.6	GH, TSH, ACTH	Severe	Yes	No	No	4.5	Never treated (resolved at 6 mo of age)	—	—
10	7.8	7.8	1.5	GH, TSH	Moderate	No	No	No	1.5	Yes	600	21.3
11	23.0	22.1	0.7	GH	Absent	No	No	No	—	Yes	600	8.5^b
12	8.0	7.8	−0.5	GH	Severe	Yes	No	Yes	4.1	Stopped at the age 3.6 y	No	No

Patient No.

Age, y

Follow-up Duration, y

BMI, SDS

Anterior Pituitary Dysfunction^a

Neuro- Developmental Delay

Seizures

Visual Impairment

Use of Sleep Medication

Duration of Enteral Nutritional and Fluid Support, y

DDAVP Treatment at the Last Evaluation

DDAVP Oral Melt/Tablets

Dose μg/d

Dose μg/kg/d

5.0

4.9

0.5

GH, TSH, ACTH

Severe

Yes

—

Yes

105

6.8

8.1

7.8

−1.7

GH, TSH, ACTH

Moderate

Yes

—

Yes

1.6

1.5

1.3

2.5

GH, TSH, ACTH

Severe

Yes

0.3

Yes

1.2

16.4

16.0

−0.2

GH, TSH

Severe

Yes

—

Yes

2.1^b

3.1

2.5

0.2

Moderate

Yes

—

Yes

150

10.3

20.0

19.8

2.3

Moderate

—

Yes

700

12.7^b

18.4

18.3

0.6

GH, TSH, ACTH, FSH-LH

Absent

—

Yes

180

3.1

16.8

1.8

GH, TSH, ACTH, FSH-LH

Absent

—

Stopped at the age 2.5 y

—

6.2

6.0

2.6

GH, TSH, ACTH

Severe

Yes

4.5

Never treated (resolved at 6 mo of age)

—

7.8

1.5

GH, TSH

Moderate

1.5

Yes

600

21.3

23.0

22.1

0.7

Absent

—

Yes

600

8.5^b

8.0

7.8

−0.5

Severe

Yes

4.1

Stopped at the age 3.6 y

Patient No.	Age, y	Follow-up Duration, y	BMI, SDS	Anterior Pituitary Dysfunction^a	Neuro- Developmental Delay	Seizures	Visual Impairment	Use of Sleep Medication	Duration of Enteral Nutritional and Fluid Support, y	DDAVP Treatment at the Last Evaluation	DDAVP Oral Melt/Tablets
1	5.0	4.9	0.5	GH, TSH, ACTH	Severe	Yes	Yes	Yes	—	Yes	105	6.8
2	8.1	7.8	−1.7	GH, TSH, ACTH	Moderate	No	Yes	No	—	Yes	30	1.6
3	1.5	1.3	2.5	GH, TSH, ACTH	Severe	Yes	Yes	Yes	0.3	Yes	15	1.2
4	16.4	16.0	−0.2	GH, TSH	Severe	Yes	Yes	No	—	Yes	85	2.1^b
5	3.1	2.5	0.2	GH	Moderate	No	Yes	No	—	Yes	150	10.3
6	20.0	19.8	2.3	No	Moderate	No	No	No	—	Yes	700	12.7^b
7	18.4	18.3	0.6	GH, TSH, ACTH, FSH-LH	Absent	No	No	No	—	Yes	180	3.1
8	16.8	16.8	1.8	GH, TSH, ACTH, FSH-LH	Absent	No	No	No	—	Stopped at the age 2.5 y	—	—
9	6.2	6.0	2.6	GH, TSH, ACTH	Severe	Yes	No	No	4.5	Never treated (resolved at 6 mo of age)	—	—
10	7.8	7.8	1.5	GH, TSH	Moderate	No	No	No	1.5	Yes	600	21.3
11	23.0	22.1	0.7	GH	Absent	No	No	No	—	Yes	600	8.5^b
12	8.0	7.8	−0.5	GH	Severe	Yes	No	Yes	4.1	Stopped at the age 3.6 y	No	No

Table 3.

Open in new tab

Characteristics of the 12 Patients at the Last Evaluation

Patient No.	Age, y	Follow-up Duration, y	BMI, SDS	Anterior Pituitary Dysfunction^a	Neuro- Developmental Delay	Seizures	Visual Impairment	Use of Sleep Medication	Duration of Enteral Nutritional and Fluid Support, y	DDAVP Treatment at the Last Evaluation	DDAVP Oral Melt/Tablets
Patient No.	Age, y	Follow-up Duration, y	BMI, SDS	Anterior Pituitary Dysfunction^a	Neuro- Developmental Delay	Seizures	Visual Impairment	Use of Sleep Medication	Duration of Enteral Nutritional and Fluid Support, y	DDAVP Treatment at the Last Evaluation	Dose μg/d	Dose μg/kg/d
1	5.0	4.9	0.5	GH, TSH, ACTH	Severe	Yes	Yes	Yes	—	Yes	105	6.8
2	8.1	7.8	−1.7	GH, TSH, ACTH	Moderate	No	Yes	No	—	Yes	30	1.6
3	1.5	1.3	2.5	GH, TSH, ACTH	Severe	Yes	Yes	Yes	0.3	Yes	15	1.2
4	16.4	16.0	−0.2	GH, TSH	Severe	Yes	Yes	No	—	Yes	85	2.1^b
5	3.1	2.5	0.2	GH	Moderate	No	Yes	No	—	Yes	150	10.3
6	20.0	19.8	2.3	No	Moderate	No	No	No	—	Yes	700	12.7^b
7	18.4	18.3	0.6	GH, TSH, ACTH, FSH-LH	Absent	No	No	No	—	Yes	180	3.1
8	16.8	16.8	1.8	GH, TSH, ACTH, FSH-LH	Absent	No	No	No	—	Stopped at the age 2.5 y	—	—
9	6.2	6.0	2.6	GH, TSH, ACTH	Severe	Yes	No	No	4.5	Never treated (resolved at 6 mo of age)	—	—
10	7.8	7.8	1.5	GH, TSH	Moderate	No	No	No	1.5	Yes	600	21.3
11	23.0	22.1	0.7	GH	Absent	No	No	No	—	Yes	600	8.5^b
12	8.0	7.8	−0.5	GH	Severe	Yes	No	Yes	4.1	Stopped at the age 3.6 y	No	No

Patient No.	Age, y	Follow-up Duration, y	BMI, SDS	Anterior Pituitary Dysfunction^a	Neuro- Developmental Delay	Seizures	Visual Impairment	Use of Sleep Medication	Duration of Enteral Nutritional and Fluid Support, y	DDAVP Treatment at the Last Evaluation	DDAVP Oral Melt/Tablets
Patient No.	Age, y	Follow-up Duration, y	BMI, SDS	Anterior Pituitary Dysfunction^a	Neuro- Developmental Delay	Seizures	Visual Impairment	Use of Sleep Medication	Duration of Enteral Nutritional and Fluid Support, y	DDAVP Treatment at the Last Evaluation	Dose μg/d	Dose μg/kg/d
1	5.0	4.9	0.5	GH, TSH, ACTH	Severe	Yes	Yes	Yes	—	Yes	105	6.8
2	8.1	7.8	−1.7	GH, TSH, ACTH	Moderate	No	Yes	No	—	Yes	30	1.6
3	1.5	1.3	2.5	GH, TSH, ACTH	Severe	Yes	Yes	Yes	0.3	Yes	15	1.2
4	16.4	16.0	−0.2	GH, TSH	Severe	Yes	Yes	No	—	Yes	85	2.1^b
5	3.1	2.5	0.2	GH	Moderate	No	Yes	No	—	Yes	150	10.3
6	20.0	19.8	2.3	No	Moderate	No	No	No	—	Yes	700	12.7^b
7	18.4	18.3	0.6	GH, TSH, ACTH, FSH-LH	Absent	No	No	No	—	Yes	180	3.1
8	16.8	16.8	1.8	GH, TSH, ACTH, FSH-LH	Absent	No	No	No	—	Stopped at the age 2.5 y	—	—
9	6.2	6.0	2.6	GH, TSH, ACTH	Severe	Yes	No	No	4.5	Never treated (resolved at 6 mo of age)	—	—
10	7.8	7.8	1.5	GH, TSH	Moderate	No	No	No	1.5	Yes	600	21.3
11	23.0	22.1	0.7	GH	Absent	No	No	No	—	Yes	600	8.5^b
12	8.0	7.8	−0.5	GH	Severe	Yes	No	Yes	4.1	Stopped at the age 3.6 y	No	No

None of the patients had hyperprolactinemia.

Tablet.

This Feature Is Available To Subscribers Only